POMDOCTOR Ltd 6-K, filed Oct 19, 2026
POMDOCTOR Ltd (POM)
About this 6-K
POMDOCTOR Ltd filed this 6-K on October 19, 2026.
POMDOCTOR LIMITED has commenced termination of its American Depositary Receipt program and will list its Class A ordinary shares directly on Nasdaq under the symbol "POM" when the market opens on October 21, 2026, alongside a 10-to-1 share consolidation. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2026
Commission File Number 001-42749
POMDOCTOR LIMITED
Yongxu Industrial Park
No. 19-23 Hejing Road, Dongsha Street
Liwan District, Guangzhou
People’s Republic of China 510000
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Termination of American Depositary Receipt Program and Trade Class A Ordinary Shares on Nasdaq
As previously approved by the board of directors of POMDOCTOR LIMITED (the “Company”) on September 3, 2026 and approved by the Company’s shareholders on a non-binding advisory basis at the extraordinary general meeting of shareholders held on September 30, 2026, the Company today announced that it has commenced to terminate its American Depositary Receipt program (the “ADR Program”), including the termination of the related deposit agreement, as amended, and list the Company’s Class A ordinary shares directly on The Nasdaq Stock Market LLC (“Nasdaq”). The ADR Program to be terminated was established pursuant to the Deposit Agreement, dated October 9, 2025, as amended, among the Company, Citibank, N.A. (the “Depositary”) and the holders and beneficial owners of the American Depositary Shares (“ADSs”) issued thereunder (the “Deposit Agreement”).
The ADR Program and the Deposit Agreement are expected to terminate prior to the opening of the market on October 21, 2026. At that time, the Company’s ADSs will be mandatorily cancelled and exchanged for the Class A ordinary shares to be distributed to the ADS holders (the “Mandatory Exchange”) according to the Deposit Agreement.
Simultaneously with the effectiveness of the termination of the ADR Program, the Company will effect a share consolidation of its Class A ordinary shares and Class B ordinary shares, pursuant to which every ten (10) ordinary shares of each class will be consolidated into one (1) ordinary share of the same class (the “Share Consolidation”). As a result of the Share Consolidation and Mandatory Exchange, each holder of ten (10) ADSs will receive three (3) post-Share Consolidation Class A ordinary shares. In connection with the termination of the ADR Program and Share Consolidation, the Company plans to list its Class A ordinary shares for trading on Nasdaq in substitution for the ADSs. The Company’s Class A ordinary shares are expected to commence trading on Nasdaq when the market opens on October 21, 2026 under the symbol “POM” with the new CUSIP number G7166T112.
The Company has appointed TranShare Corporation as its transfer agent in the United States for its Class A ordinary shares.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| POMDOCTOR LIMITED | ||
| By: | /s/ Zhenyang Shi | |
| Name: | Zhenyang Shi | |
| Title: | Chairman and Chief Executive Officer | |
Date: October 19, 2026
2